Evidence mapPaperPMID 40145178Full record

ReviewExpert reviews in molecular medicine2025

Exploring organoid and assembloid technologies: a focus on retina and brain.

Sara Ouaidat, Alessandro Bellapianta, Franziska Ammer-Pickhardt, Tara Taghipour, Matthias Bolz, Ahmad Salti

Abstract readReview
In one paragraph

Review in Expert reviews in molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Single-Cell Transcriptomics onBiomedicines · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sara OuaidatResearch Group Cellular and Molecular Ophthalmology, University Clinic for Ophthalmology and Optometry, Kepler University Hospital, Johannes Kepler University Linz, Linz, Austria.ORCID 0009-0005-4640-9973
Alessandro BellapiantaResearch Group Cellular and Molecular Ophthalmology, University Clinic for Ophthalmology and Optometry, Kepler University Hospital, Johannes Kepler University Linz, Linz, Austria.ORCID 0000-0002-3375-9940
Franziska Ammer-PickhardtResearch Group Cellular and Molecular Ophthalmology, University Clinic for Ophthalmology and Optometry, Kepler University Hospital, Johannes Kepler University Linz, Linz, Austria.ORCID 0009-0005-7725-4695
Tara TaghipourResearch Group Cellular and Molecular Ophthalmology, University Clinic for Ophthalmology and Optometry, Kepler University Hospital, Johannes Kepler University Linz, Linz, Austria.ORCID 0009-0003-0754-2654
Matthias BolzResearch Group Cellular and Molecular Ophthalmology, University Clinic for Ophthalmology and Optometry, Kepler University Hospital, Johannes Kepler University Linz, Linz, Austria.ORCID 0000-0001-8691-5276
Ahmad SaltiResearch Group Cellular and Molecular Ophthalmology, University Clinic for Ophthalmology and Optometry, Kepler University Hospital, Johannes Kepler University Linz, Linz, Austria.ORCID 0000-0002-7678-0125

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe recent emergence of three-dimensional organoids and their utilization as in vitro disease models confirmed the complexities behind organ-specific functions and unravelled the importance of establishing suitable human models for various applications. Also, in light of persistent challenges associated with their use, researchers have been striving to establish more advanced structures (i.e. assembloids) that can help address the limitations presented in the current organoids.

methodsIn this review, we discuss the distinct organoid types that are available to date, with a special focus on retinal and brain organoids, and highlight their importance in disease modelling.

resultsWe refer to published research to explore the extent to which retinal and brain organoids can serve as potential alternatives to organ/cell transplants and direct our attention to the topic of photostimulation in retinal organoids. Additionally, we discuss the advantages of incorporating microfluidics and organ-on-a-chip devices for boosting retinal organoid performance. The challenges of organoids leading to the subsequent development of assembloid fusion models are also presented.

conclusionIn conclusion, organoid technology has laid the foundation for generating upgraded models that not only better replicate in vivo systems but also allow for a deeper comprehension of disease pathophysiology.

Indexed as

BrainOrganoidsRetinaAnimalsHumans3D modelsassembloidsaxonal projectionsbrain organoids (BOs)organoidsretinal ganglionic cells (RGCs)retinal organoids (ROs)

Identifiers

PMID40145178
PMCPMC12011387

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.